Vildagliptin + Metformin hydrochloride (SR)Third Party Manufacturing in India

Vildagliptin + Metformin hydrochloride (SR) works by utilizing dual therapeutic pathways to improve glycemic control. Vildagliptin selectively inhibits the DPP-4 enzyme to increase levels of active endogenous incretin hormones, enhancing glucose-dependent insulin secretion. Metformin hydrochloride works via a sustained-release matrix to lower hepatic glucose output and increase peripheral glucose uptake over an extended period. Unlike immediate-release combinations, it reduces gastrointestinal side effects and maintains stable blood drug concentrations. It is highly effective and well-tolerated for convenient once-daily dosing.

Therapeutic Uses

• Type 2 Diabetes Care: Optimizes long-term glycemic control when metformin monotherapy cannot reach HbA1c targets.
• Sustained Glucose Control: Provides continuous 24-hour management of fasting and postprandial blood glucose levels.
• Insulin Sensitivity Enhancement: Lowers peripheral tissue resistance to endogenous insulin while protecting pancreatic beta cells.

Why Manufacturers Choose Vildagliptin + Metformin hydrochloride (SR)

Sustained-release combinations offer excellent patient adherence and are highly valued in chronic care portfolios. Partnering for Vildagliptin + Metformin hydrochloride (SR) third party manufacturing in India via Celesta gives you access to advanced hydrophilic or lipophilic polymer matrix technology for controlled drug release. Our manufacturing partners process premium CAS 274901-16-5 active materials in fully compliant WHO-GMP facilities. Their adherence to WHO-GMP standards ensures consistent sustained-release profiles and prevents dose dumping.